Clinical Trials Logo

Carcinoma in Situ clinical trials

View clinical trials related to Carcinoma in Situ.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06393543 Not yet recruiting - Ovarian Carcinoma Clinical Trials

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis

STICRISC
Start date: June 2024
Phase:
Study type: Observational [Patient Registry]

To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma). Moreover, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of peritoneal carcinomatosis and to report the findings of additional diagnostics.

NCT ID: NCT06356012 Not yet recruiting - Biomarkers Clinical Trials

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod

Start date: April 2, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.

NCT ID: NCT06333743 Not yet recruiting - Clinical trials for High-Grade Squamous Intraepithelial Lesions

Laser Ablation in the Treatment of High-grade Cervical Lesions

Start date: May 2024
Phase: N/A
Study type: Interventional

Cervical laser ablation is an effective, minimally invasive treatment with a low incidence of perinatal complications and minimal impact on fertility. Research has confirmed that laser ablation treatment of cervical HSIL (including CIN2 and CIN3) is effective and feasible and is useful for young CIN3 patients who wish to get pregnant in the future. There have been no randomized clinical trials of laser ablation therapy for cervical HSIL in Chinese women. This study focuses on the application of laser ablation in the treatment of cervical HSIL, explores the efficacy, feasibility, and safety of laser ablation in the treatment of cervical HSIL, and strives to promote the reasonable application of laser ablation in the treatment of cervical HSIL.

NCT ID: NCT06310369 Not yet recruiting - Bladder Cancer Clinical Trials

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Start date: March 1, 2025
Phase: Phase 2
Study type: Interventional

We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has yet to be fully explored.

NCT ID: NCT06273553 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

NCT ID: NCT06263582 Not yet recruiting - Cervix Cancer Clinical Trials

Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer treatment. A secondary objective is to investigate safety among study participants.

NCT ID: NCT06258564 Not yet recruiting - Recurrence Clinical Trials

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Start date: May 1, 2024
Phase:
Study type: Observational

Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.

NCT ID: NCT06219018 Not yet recruiting - Clinical trials for High Risk Human Papillomavirus

Effect of Honey For CIN II

HoneyForCIN2
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase inthe normalization of CIN II lesions compared to expectant management.

NCT ID: NCT06217458 Not yet recruiting - DCIS Clinical Trials

The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS

CEMinDCIS
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or/and mastectomy) is lower in the group of patients who underwent standard preoperative mammography and CEM to assess the extent of DICS, compared to the group of patients for whom the preoperative assessment of the extent of in situ breast cancer was not performed using one of the imaging techniques with contrast medium such as contrast mammography or magnetic resonance imaging.

NCT ID: NCT06195306 Not yet recruiting - Breast Carcinoma Clinical Trials

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Start date: June 16, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.